Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Julie Denny
  • January 20, 2015
  • News

Dr Moniola Olusanjo appointed Compliance Manager

Dr Moniola Olusanjo appointed Compliance Manager

Research Partnership is delighted to welcome Dr Moniola Olusanjo to the company’s London headquarters in the role of Compliance Manager.

As part of Research Partnership’s ongoing industry commitment to compliance, Moniola’s appointment expands the company’s existing compliance capabilities and the role will encompass working with existing regional compliance officers to oversee compliance requirements for the company across all six offices globally.As Compliance Manager, Moniola will seek to continually improve and develop existing procedures, ensure that all 120 researchers training is complete and up-to-date, ensuring that Research Partnership adheres to all client, governmental and regional legal and ethical requirements globally. She will also act as client and industry liaison to ensure Research Partnership abides by and meets requirements, as well as to keep abreast of evolving initiatives and advancements within the pharmaceutical market research compliance industry.

read more »

  • Posted by Julie Denny
  • January 20, 2015
  • Webinars

Uncovering hidden insights into patient compliance

Uncovering hidden insights into patient compliance

Pharma companies are increasingly looking for ways to provide “beyond the pill" services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment regimen. But assessing compliance can be difficult with traditional methods giving biased results. Would the use of digital techniques elicit greater insights?

read more »

Taking a holistic view when exploring compliance

Our client wanted to address the issues and barriers surrounding non-compliance with their biologic drug.

The assumption going into the study was that the barriers to compliance existed among the patients themselves. We therefore employed a one-to-one methodology with patients who were recruited to represent the various stages in the patient journey as they transitioned to biologics. However, we also felt it was important to gain the perspectives of the healthcare professional managing the patients in order to gain a more holistic view of the patient experience.

read more »